Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Graft Polymer (UK) PLC ( (GB:SVNS) ) just unveiled an update.
Solvonis Therapeutics plc has successfully raised approximately £2.0 million through the issuance of new ordinary shares, representing a significant portion of its pre-fundraise share capital. This capital raise, facilitated by joint brokers Allenby Capital Limited and Singer Capital Markets Securities Limited, is expected to enhance Solvonis’s financial position and support its strategic initiatives in the mental health therapeutics sector. The new shares will be admitted to trading on the London Stock Exchange, with trading expected to commence on 27 May 2025. The fundraise also includes participation from key company directors, highlighting confidence in the company’s future prospects.
More about Graft Polymer (UK) PLC
Solvonis Therapeutics plc is an innovative biotechnology company focused on co-developing therapeutics for mental health disorders. The company operates within the biotechnology industry, aiming to address unmet needs in mental health treatment through its specialized therapeutic offerings.
Average Trading Volume: 7,611,024
Technical Sentiment Signal: Sell
Current Market Cap: £3.79M
For detailed information about SVNS stock, go to TipRanks’ Stock Analysis page.